Today's Trend
Aura Biosciences, Inc. (NASDAQ: AURA) is seeing mixed investor sentiment, with shares edging higher despite recent pressure from a quarterly earnings miss and a workforce reduction. Positive analyst revisions and long-term expectations are supporting the stock, while near-term losses and trial-funding concerns remain headwinds.
- HC Wainwright maintained a Buy rating and an $18 price target while raising its EPS forecasts for 2026 through 2030. The firm now expects narrower losses in the next several years and forecasts a return to profitability by 2030, when it projects $0.56 in EPS. Q1 Earnings Forecast for AURA Issued By HC Wainwright
- Analyst sentiment remains broadly constructive toward Aura’s healthcare opportunity. Aura was included among healthcare stocks highlighted as having bullish analyst coverage, which may help offset concerns about its ongoing losses. Analysts Are Bullish on Top Healthcare Stocks
- Aura cut approximately 20% of its workforce to preserve cash and fund its late-stage eye-cancer trial. The move could extend the company’s runway, but it also highlights the financial demands and execution risks associated with advancing its clinical program. Aura Cuts 20% of Staff to Fund Late-Stage Trial
- Aura reported quarterly EPS of negative $0.48, missing the negative $0.38 analyst consensus. The earnings shortfall triggered a gap-down move and reinforces concerns about the company’s continuing cash burn and lack of near-term profitability. Aura Biosciences Shares Gap Down Following Weak Earnings